Novel High-Dose Chemotherapy Regimens in Relapsed/Refractory Germ Cell Cancer: Have We Made Progress?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41231121.
- Also identified by DOI 10.1158/1078-0432.CCR-25-3334.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sequential carboplatin/etoposide-based high-dose chemotherapy with stem cell support is a standard therapy option for relapsed germ cell tumors, resulting in cure for approximately 50% of patients. In a recent single-center phase II study, results were reported for a novel combination including gemcitabine, melphalan, docetaxel, and carboplatin. See related article by Nieto et al., p. 300.
Medical subject headings
- Neoplasms, Germ Cell and Embryonal
- Antineoplastic Combined Chemotherapy Protocols
- Neoplasm Recurrence, Local